Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol for hypermetabolic response in adults with acute burns
IRCT20230301057584N1Phase 3Completed
- Sponsor
- Hormozgan University of Medical Sciences
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of propranolol in burn injury (2 arms), sponsored by Hormozgan University of Medical Sciences. Primary endpoints: Blood pressure, Heart rate and 2 more. Started Apr 2023; status: completed.
02
Drugs
propranolol
03
Conditions
burn injury
Beyond the preview
Go deeper on IRCT20230301057584N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230301057584N1.